May 3 P&P Quick Takes: FDA updates

Draft guidance on ADHD products
In its first draft guidance on developing drugs for ADHD, FDA outlined clinical trial designs and acceptable primary endpoints, as well as recommended safety assessments for both new molecular entities and 505(b)(2) products. FDA said the draft is consistent with the agency's approach already in practice. Comments are due July 3...